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Abstract
Bacground/Aim. Preterm delivery is one of the most com-
mon complications in pregnancy, and it is the major cause (75–
80%) of all neonatal deaths. Bacterial vaginosis predisposes to
an increased risk of preterm delivery, premature rupture of
membrane and miscarriage. In this syndrome normal vaginal
lactobacilli, which produce protective H2O2, are reduced and
replaced with anaerobic, gram-negative bacteria and others.
The aim of this study was to evaluate the influence of bacterial
vaginosis on the week of delivery and biochemical markers of
inflammation in the serum. Methods. A total of 186 pregnant
women were included into this study, between the week 16 and
19 of pregnancy. In the study group there were 76 pregnant
women with diagnosed bacterial vaginosis by the criteria based
on vaginal Gram-stain Nugent score and Amsel criteria. In the
control group there were 110 healthy women with normal
vaginal flora. Ultrasound examination was performed in both
groups. Vaginal fluid and blood samples were taken to deter-
mine biochemical markers with colorimetric methods. Results.
The week of delivery was statistically significantly shorter in the
study group and the levels of biochemical markers of inflam-
mation (C-reactive protein and fibrinogen in the serum) were
statistically significantly higher in women with bacterial vagino-
sis comparing to the control group. Also the levels of uric acid
and white blood cells in the serum were higher in the study
group compared to the control one. Conclusion. Our study
indicates that the pregnancy complicated with bacterial vagino-
sis ends much earlier than the pregnancy without it. Also,
higher levels of biochemical markers of inflammation in the se-
rum in the study group, similarly to results of other studies,
suggest that pathophysiological processes responsible for pre-
term delivery can begin very early in pregnancy.
Key words:
pregnancy; vaginosis, bacterial; premature birth; risk
factors; biological markers.
Apstrakt
Uvod/Cilj. Prevremeni poroĀaj predstavlja jednu od najÿe-
šýih akušerskih komplikacija, i kod 75–80% sluÿajeva uzro-
ÿnik je neonatalnog mortaliteta. Bakterijska vaginoza smatra
se znaÿajnim faktorom rizika od prevremenog poroĀaja,
prevremene rupture plodovih ovojaka i pobaÿaja. Nastaje
kao posledica redukcije laktobacila koji proizvode protekti-
vni H2O2, sa preovladavanjem anaerobnih, gram-negativnih
i drugih nepovoljnih bakterija. Cilj ovog rada bio je da se ut-
vrdi da li bakterijska vaginoza kod trudnica ima uticaja na
nedelju završetka poroĀaja kao i na biohemijske markere in-
flamacije u serumu. Metode. Studija je obuhvatila ukupno
186 trudnica, izmeĀu 16. i 19. nedelje gestacije. Ispitanice su
bile podeljene na grupu sa dokazanom bakterijskom vagino-
zom po Amselovim i Njudžentovim kriterijumima (n = 76) i
kontrolnu grupu sa normalnom bakterijskom florom
(n = 110). Svim trudnicama je uraĀen ultrazvuÿni pregled,
uzet bris vaginalnog sekreta i uzorak krvi za odreĀivanje bi-
ohemijskih markera inflamacije kolorimetrijskim metodama.
Rezultati. Nedelja završetka poroĀaja bila je statistiÿki zna-
ÿajno kraýa kod trudnica sa bakterijskom vaginozom u od-
nosu na kontrolnu grupu, dok su biohemijski markeri infla-
macije, C-reaktivni protein i fibrinogen, bili statistiÿki zna-
ÿajno viši u ispitivanoj grupi nego u kontrolnoj grupi. Tako-
Āe, vrednosti mokraýne kiseline i ukupnih leukocita bile su
više u ispitivanoj u odnosu na kontrolnu grupu. Zakljuÿak.
Naša istraživanja ukazuju na znatno raniji završetak poro-
Āaja kod trudnica sa bakterijskom vaginozom, kao i na to da
više vrednosti biohemijskih markera inflamacije u serumu
ispitivane grupe, sliÿno drugim istraživanjima, sugerišu da se
patofiziološki procesi odgovorni za prevremeni poroĀaj
mogu javiti vrlo rano u trudnoýi.
Kljuÿne reÿi:
trudnoýa; vaginoza, bakterijska; poroĀaj, prevremeni;
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Introduction
Bacterial vaginosis (BV) presents the adverse of vaginal
ecosystem, which results in decreasing or complete disappear-
ance of hydrogen-peroxyde producing lactobacillus and enor-
mous increase of anaerobic facultative bacteria which are 100
to 1,000 more than usual 
1–4. In non-pregnant women BV in-
creases risk of pelvic inflammatory disease (PID), postabor-
tional PID, postoperative infections and pathological cervical
changes, while in pregnancy there is higher frequency of pre-
mature rupture of membranes (PROM), preterm delivery, cho-
rioamnionitis or postpartal endometritis. It is assumed that BV
is present in 30% of pregnant women 
4, 5. In the last 20 year,
extensive studies indicated close relationship between BV and
preterm delivery, which presents one of the most important
causes of perinatal morbidity and mortality 
6–9. The exact
mechanism of BV  leading to preterm delivery is still un-
known, considering that its main feature is the absence of
signs of inflammation, low production of cytokines and the
absence of inflammatory cells such as macrophags and neu-
trophils 
8–10. However, meta-analyses indicate that as soon as
BV is diagnosed [< 20 gestational weeks (GWs)] the risk of
preterm delivery is increased 
11–13. It is assumed that the risk of
pretern delivery is associated with the type of vaginal flora and
also with the type of immune answer that controls inflamma-
tory process whose background could be found in genetic ex-
planations. The attitude of some authors 
5, 10, 14 is that asymp-
tomatic pregnant women with previous premature deliveries or
abortions in second trimester of pregnancy, should control,
and, in case of occurence of subjective complaints, cure with
vaginalets, and, in case of positive bacterial smears, systemic
antibiotic therapy should be applied.
The aim of this study was to determine a connection
between BV and the week of delivery completion, and also
to investigate if early detected BV (< 20 GW) can affect bio-
chemical markers of inflammation in the serum, in order to
evaluate the pathophysiological pathways by which BV leads
to preterm delivery.
Methods
This prospective study was conducted in the Depart-
ment of Gynecology and Obstetrics, Clinical Center of Vo-
jvodina, Novi Sad. The study included 198 pregnant women
in total who agreed to participate in research, and they con-
firmed it with their signature in accordance with the Helsinki
Declaration. The protocol was approved by the Ethics Com-
mittee of the Medical Faculty in Novi Sad and Clinical Cen-
ter of Vojvodina, Novi Sad, Serbia.
All the pregnant women included in the research (ges-
tational age between the GW 16 and 19 had an ultrasound
examination to assess gestational age, fetal growth and de-
velopment and viability of fetus. After that swabs of vaginal
secretion and blood samples were taken. All the pregnant
women were included in the study and monitored until the
end of pregnancy.
All the participating women were divided into two
groups: the study group (n  =  80) consisted of pregnant
women with  BV diagnosed by the Amsel (score  3)  and
Nugent criteria (score  7) 
15, 16, and the control group of
pregnant women with normal vaginal flora. Pregnant women
with the diagnosed intermediate vaginal flora were excluded
from the research. During monitoring 12 women in total
were excluded from the research. One pregnant woman had a
spontaneous abortion in  GW 17, one woman in GW 22 was
diagnosed with  fetal anomalies, and one pregnant woman
had preterm delivery due to oligohydramnion. Total of 9
pregnant women were excluded due to inability of monitor-
ing (or did not appear in Clinical Center of Vojvodina or we
could not get information by telephone). Finally, the control
group included of 110 pregnant women, and the study group
included 76 pregnant women. Other factors that could lead to
preterm delivery were the criteria for exclusion of pregnant
women from the research. These factors were: multiple
pregnancy, polyhydramnion, placenta praevia, diseases of
mother and fetus (diabetes, hypertension, preeclampsia, ec-
lampsia, kidney and heart diseases of mother, urinary infec-
tions, genetic malformations of fetus, intrauterine growth
retardation), the local factors: anatomical malformations of
uterus and vagina, cervical insufficiency, other genital infec-
tions, uterine tumors, then all diseases that can affect the
level of biochemical markers in the serum such as autoim-
mune diseases and hormone disbalance, and also pregnant
women younger than 18 and use of antibiotics just before
conception and during pregnancy.
Vaginal swab was taken from lateral wall of vagina
and used to create direct preparation stained by Gram and
scored by Nugent method and Amsel method for diagnosis
of BV 
14–16.
Hematological parameters were determined on an
automatic hematological analyzer ABX Micros CRP200
(HoribaABX Diagnostics). On the same machine concentra-
tion of C-reactive protein (CRP) was determined by nephe-
lometric method.
Glucose in the serum was determined by the enzyme
referent method with hexokinase with commercial reagent
(Roshe Diagnostics) on a biochemical analyzer Cobas Inte-
gra 400 plus. Uric acid was determined by the enzyme col-
orimetric method with uricase and peroxidase with commer-
cial reagent (Roshe Diagnostics) on a biochemical analyzer
Cobas Integra 400 plus.
Fibrinogen concentration was determined on a BFT II
Fibrintimer (Siemens Health Care Diagnostics) with a modi-
fied method by Klaus with Multifibren U-reagent.
Statistical analysis was done by statistical package
SPSS (ver.13) for Windows, and p value less than 0.05 were
considered statistically significant. Student’s t-test and
Mann-Whitney test were used to compare variables between
the two groups.
Results
The  study included 76 pregnant women of the study
group, aged between 20 and 41, and 110 pregnant women of
the control group, aged between 19 and 42. Table 1 shows
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search. There was a statistically significant difference be-
tween the groups in the week of completion of pregnancy
(p < 0.001), while there was no statistically significant dif-
ference between the age and the weeks of gestation during
swab sampling.
Table 2 shows percentage ratio of vaginal deliveries
(VG) and Cesarean sections (CS) in the study and the control
group.
Table 2
Mode of delivery
Mode of delivery Group VG CS Total
Control, n (%) 85 (77.1) 25 (22.9) 110 (100)
Study, n (%) 57 (75.0) 19 (25.0) 76 (100)
Total, n (%) 142 (100) 44 (100) 186 (100)
VG – vaginal delivery; CS – Cesarean sections.
Table 3 shows comparison of the mean values of uric
acid, glucose, CRP, fibrinogen and hematological parameters
in blood between the study and the control group. The values
of CRP and fibrinogen were statistically significantly higher
in pregnant women with BV compared to the control group
(p < 0.001).
Discussion
BV is a syndrome resulting in a significant reduction of
lactobacilli necessary for the creation of H2O2, which enables
propagation of Gardanella vaginalis, Mycoplasma hominis,
anaerobes etc. 
17–20. There is no doubt that BV and preterm
delivery are associated. Currently, a number of studies have
been aimed at finding answers to questions: “What are
pathophysiological mechanisms linking BV and preterm de-
livery?”, and “Why are a large number of pregnancies, re-
gardless of whether BV is diagnosed by clinical or micro-
scopic methods, spontaneously resolved without conse-
quences for mother or child and only 10–15% have a pre-
mature birth?“, “Why is BV detected in early pregnancy
more associated with preterm delivery than the one diag-
nosed later in pregnancy?” 
21–24. It is assumed that one of the
main factors that makes finding the answers to these ques-
tions difficult, lies in the name of the syndrome “vaginosis”
and not vaginitis which explains that there is the absence of
vaginal inflammatory process 
2, 19. It is assumed that there are
several factors that can individually or jointly increase the
risk of preterm delivery. Microorganisms that cause BV can
ascendantly spread from lower parts of genital tract to upper
parts and lead to chorioamnionitis, a preterm rupture of fetal
membranes and preterm delivery 
3, 25, 26. Then, microorgan-
isms can produce proteolytic enzymes that increase epithe-
lium permeability in vagina, and allow passage of very
pathogenic microorganisms 
27, 28. Results of other researches
indicate the role of local immunological factors, genetically
predisposed and depending on their presentation to microor-
ganisms causing BV, local inflammatory mediators such as
cytokines, chemokines, and growth factors that determine
what kind of consequences will appear. It is also assumed
that the increased production of local cytokines-
prostaglandins, can trigger preterm delivery 
29–32.
Metronidazole is the drug of choice for bacterial vagi-
nosis. However, application of imidazole derivatives in
pregnancy is still debatable, although recent studies indi-
cate that there is no evidence of teratogenicity of this drug;
it is still necessary to estimate the maternal benefit in rela-
tion to fetal-neonatal risk 
6. It has been shown that treat-
ment with metronidazole in a dose of 400 mg 2 times a day
for 5 days, and of 500 mg 2 times a day for 7 days, is more
effective than giving 2 g in a single dose. Intravaginal met-
ronidazole gel (0.75%) and clindamycin intravaginal cream
(2%) have similar efficiency, because theoretically me-
tronidazol is less active to lactobacilli than clindamycin,
while clindamycin is more active to the most of the bacteria
Table 3
Mean values of hematological parameters, C-reactive protein (CRP), fibrinogen, uric acid and glucose
Study group (n = 76) Control group (n = 110) Variables ʉ ± SD ʉ ± SD p
Uric acid (μmol/L) 170.43 ± 110.81 150.33 ± 96.84 0.520
Glucose (mmol/L) 2.99 ± 1.71 2.83 ± 1.82 0.768
CRP (mg/L) 7.07 ± 6.93 2.60 ± 1.50 < 0.001*
Fibrinogen (g/L) 4.44 ± 0.52 4.12 ± 0.36 < 0.001*
Leucocytes (x 10 
9/L) 8.75 ± 1.69 8.14 ± 1.75 0.129
Erythrocytes (x 10
12/L) 3.96 ± 0.42 4.04 ± 0.41 0.408
Thrombocytes (x 10
9/L) 225.57 ± 52.73 204.91 ± 53.61 0.098
Hemoglobin (g/L) 114.80 ± 9.19 118.63 ± 13.78 0.151
*statistically significant difference.
Table 1
Age of pregnant woman, gestational week (GW) during swab sample taking and
the week of pregnancy completion (CW)
Study group (n = 76) Control group (n = 110) p Parameter ʉ ± SD ʉ ± SD
Age (years) 31.47 ± 5.51 31.44 ± 5.86 0.974
GW 17.50 ± 0.808 17.41 ± 0.670 0.489
CW 37.72 ± 3.948 39.59 ± 1.06 < 0.001*
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that are related to BV 
33. However, peroral application of
clindamycin can be accompanied with appearance of ma-
ternal pseudomembranous colitis, which is more often in-
pregnant than in non-pregnant women. Application of 2%
klindamycin vaginal cream one time a day is suggested,
while in second and third semester of pregnancy such
women can apply antibiotic therapy with: 500 mg metroni-
dazol 2 times for 7 days, or 400 mg metronidazol 2 times
for 2 days (if  necessary, repeat after 4 weeks) and 250 mg
of metronidazol i 333 mg erythromycina 3 times for 7 days.
The treatment reduces the incidence of preterm delivery in
pregnant women with increased risk (history of preterm
deliveries in previous pregnancies) 
33. A group of authors 
33
from Medical Faculty in Wroclaw, Poland, in their reserach
from 2006 determined the importance of using hydrophilic
vaginal tablets containing complex of lactic acid and Eu-
dragit E-100. It turned out that these vaginal tablets are
very useful in therapy of symptoms of BV in pregnant
women. During the therapy there were no side effects, and
after the therapy vaginal mucosa did not show signs of ir-
ritation or allergic reactions 
34–36.
The results of our study agree are in accordance with
those in the literature 
1, 7, 16, 28. There is a statistically signifi-
cant difference in week of pregnancy completion in women
with BV compared to women with normal vaginal flora,
while the serum levels of biochemical markers of inflamma-
tion, CRP and fibrinogen, also show statistically significantly
higher values in the study group than in the control one. The
values of uric acid and total number of leukocytes are higher
in the study than in the control group. There is also a higher
number of Cesarean deliveries in the group with BV than in
the control group.
Conclusion
The results of our study indicate a significantly earlier
delivery in pregnant women with the diagnosed bacterial
vaginosis in early pregnancy, and also statistically signifi-
cantly higher values of C-reactive protein and fibrinogen in
pregnant women with bacterial vaginosis, that can help in
further research with both existing and possible new mark-
ers, which could help in clarification of pathogenetic mecha-
nisms which link bacterial vaginosis and preterm delivery, as
well as in identification of women with the risk of preterm
delivery caused by infection, at the same time. However, it is
also necessary to expand existing researches and include ge-
netic analysis, i.e. examine the response of genotype and
immunologically different phenotypes in dependence on
change of microenvironment or inflammation, in order to
explain pathophysiology of preterm delivery.
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